San Diego’s Trovagene will partner with Nektar Therapeutics to explore combining their two drug candidates to treat metastatic colon cancer.
Trovagene brings to the table onvansertib, which will be evaluated with Nektar Therapeutics’ onzeald in preclinical models. Besides the research collaboration, onvansertib is undergoing clinical trials for other indications.
"Our research partnership with Nektar is a key milestone achievement in the advancement of our onvansertib clinical development program," said Mark Erlander, chief scientific officer of Trovagene, in a news release.
Trovagene is developing drugs that target cell division, in hopes of treating cancer, leukamias, lymphomas and solid tumors.